These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
551 related articles for article (PubMed ID: 29635026)
1. NTM drug discovery: status, gaps and the way forward. Wu ML; Aziz DB; Dartois V; Dick T Drug Discov Today; 2018 Aug; 23(8):1502-1519. PubMed ID: 29635026 [TBL] [Abstract][Full Text] [Related]
2. Medications and monitoring in nontuberculous mycobacteria infections. Egelund EF; Fennelly KP; Peloquin CA Clin Chest Med; 2015 Mar; 36(1):55-66. PubMed ID: 25676519 [TBL] [Abstract][Full Text] [Related]
3. What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward? Timmins GS Expert Opin Drug Discov; 2020 Jan; 15(1):7-9. PubMed ID: 31566439 [No Abstract] [Full Text] [Related]
4. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. van Ingen J; Boeree MJ; van Soolingen D; Mouton JW Drug Resist Updat; 2012 Jun; 15(3):149-61. PubMed ID: 22525524 [TBL] [Abstract][Full Text] [Related]
9. Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria. Soni I; De Groote MA; Dasgupta A; Chopra S J Med Microbiol; 2016 Jan; 65(1):1-8. PubMed ID: 26515915 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Huh HJ; Kim SY; Jhun BW; Shin SJ; Koh WJ Infect Genet Evol; 2019 Aug; 72():169-182. PubMed ID: 30315892 [TBL] [Abstract][Full Text] [Related]
11. Antimycobacterial strategies to evade antimicrobial resistance in the nontuberculous mycobacteria. Millar BC; Moore JE Int J Mycobacteriol; 2019; 8(1):7-21. PubMed ID: 30860173 [TBL] [Abstract][Full Text] [Related]
12. Autophagy and Host Defense in Nontuberculous Mycobacterial Infection. Silwal P; Kim IS; Jo EK Front Immunol; 2021; 12():728742. PubMed ID: 34552591 [TBL] [Abstract][Full Text] [Related]
15. The treatment of rapidly growing mycobacterial infections. Kasperbauer SH; De Groote MA Clin Chest Med; 2015 Mar; 36(1):67-78. PubMed ID: 25676520 [TBL] [Abstract][Full Text] [Related]
16. MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections. Sethiya JP; Sowards MA; Jackson M; North EJ Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867307 [TBL] [Abstract][Full Text] [Related]
17. A Comparative Genomics Approach for Shortlisting Broad-Spectrum Drug Targets in Nontuberculous Mycobacteria. Swain A; Gnanasekar P; Prava J; Rajeev AC; Kesarwani P; Lahiri C; Pan A Microb Drug Resist; 2021 Feb; 27(2):212-226. PubMed ID: 32936741 [TBL] [Abstract][Full Text] [Related]
18. Efflux Pump Inhibitors Against Nontuberculous Mycobacteria. Rindi L Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545436 [TBL] [Abstract][Full Text] [Related]
19. A review of current and promising nontuberculous mycobacteria antibiotics. Cantelli CR; Dassonville-Klimpt A; Sonnet P Future Med Chem; 2021 Aug; 13(16):1367-1395. PubMed ID: 34165325 [TBL] [Abstract][Full Text] [Related]
20. New insights in the treatment of nontuberculous mycobacterial pulmonary disease. Ruth MM; van Ingen J Future Microbiol; 2017 Oct; 12():1109-1112. PubMed ID: 28972416 [No Abstract] [Full Text] [Related] [Next] [New Search]